November 18, 2026
Health news, explained with evidence
LIVE

Navigating Treatment Shifts in Duchenne Muscular Dystrophy

❤️ Conditions & Care 2 min read 👁 6

Experts outline the clinical considerations for adjusting or changing therapies in Duchenne muscular dystrophy management, highlighting the role of side effect tolerance.

Navigating Treatment Shifts in Duchenne Muscular Dystrophy❤️Conditions & Care

Photo: everydayhealth.com

Key points

  • DMD treatments focus on slowing disease progression, making short-term efficacy hard to measure.
  • Side effect tolerance, particularly regarding weight gain and behavior, often drives treatment adjustments.
  • Alternative steroids like deflazacort and vamorolone offer potential benefits regarding side-effect profiles but depend on insurance approval.

For individuals and families managing Duchenne muscular dystrophy (DMD), determining the right time to modify or discontinue a therapeutic regimen presents a unique clinical challenge. Pediatric neurologist Dr. Jessie Nance of Johns Hopkins Children’s Center explains that because current medications are designed to slow disease progression rather than yield visible improvements, assessing efficacy from month to month is complex. While various assessments track disease trajectory, clinicians typically look toward patient tolerance of side effects rather than a specific numeric threshold to guide adjustments.

Corticosteroids remain the foundational standard of care for DMD, frequently helping patients preserve independent walking ability for an additional one to two years. However, common adverse effects such as significant weight gain and behavioral changes can prompt families to seek alternatives. Dr. Nance notes that adjusting the medication schedule—such as moving to alternate-day or weekend dosing—is often explored before stopping treatment entirely, though abrupt cessation remains dangerous due to risks like adrenal insufficiency. When schedule changes are insufficient, physicians may consider alternative steroid formulations such as deflazacort (Emflaza) or the newer agent vamorolone (Agamree), which aim to reduce impacts on bone health, growth, and behavior, subject to insurance coverage limitations.

What to know: Treatment decisions in DMD require careful collaboration between families and neurology care teams. Never stop or alter a treatment plan without professional medical guidance.

Source everydayhealth.com — everydayhealth.com/genetic-diseases/should-you-change-your-duchenne… ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.